Spero Therapeutics, Inc. (SPRO)
NASDAQ: SPRO · Real-Time Price · USD
1.155
-0.015 (-1.28%)
Oct 8, 2026, 11:45 AM EDT - Market open
Spero Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 47 | 66.8 | 47.98 | 103.78 | 53.51 | 18.26 | |
Revenue Growth | -3.25% | 39.24% | -53.77% | 93.95% | 193.10% | 95.67% |
Cost of Revenue | 20.53 | 38.47 | 96.76 | 51.44 | 47.59 | 64.53 |
Gross Profit | 26.47 | 28.34 | -48.78 | 52.34 | 5.92 | -46.27 |
Selling, General & Admin | 19.85 | 21.18 | 23.7 | 25.55 | 36.48 | 41.7 |
Operating Expenses | 19.85 | 21.18 | 23.7 | 25.55 | 36.48 | 41.7 |
Operating Income | 6.61 | 7.16 | -72.48 | 26.79 | -30.57 | -87.97 |
Interest Expense | - | - | - | - | -2.61 | -1.94 |
Interest & Investment Income | 1.62 | 2.51 | 4.74 | 3.94 | 1.11 | 0.35 |
Other Non Operating Income (Expenses) | -0 | 0.01 | 0.06 | -0.01 | 0.86 | -0.19 |
EBT Excluding Unusual Items | 8.23 | 9.68 | -67.69 | 30.71 | -31.2 | -89.76 |
Merger & Restructuring Charges | - | -0.26 | -0.88 | - | -11.63 | - |
Asset Writedown | -0.59 | -0.59 | - | -5.31 | - | - |
Other Unusual Items | - | - | - | - | -3.58 | - |
Pretax Income | 7.64 | 8.83 | -68.57 | 25.4 | -46.42 | -89.76 |
Income Tax Expense | 0.26 | 0.26 | - | 2.6 | - | - |
Earnings From Continuing Operations | 7.38 | 8.57 | -68.57 | 22.81 | -46.42 | -89.76 |
Net Income | 7.38 | 8.57 | -68.57 | 22.81 | -46.42 | -89.76 |
Net Income to Common | 7.38 | 8.57 | -68.57 | 22.81 | -46.42 | -89.76 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 57 | 56 | 54 | 53 | 38 | 31 |
Shares Outstanding (Diluted) | 60 | 59 | 54 | 53 | 38 | 31 |
Shares Change | 9.05% | 9.25% | 1.98% | 40.98% | 21.65% | 38.01% |
EPS (Basic) | 0.13 | 0.15 | -1.27 | 0.43 | -1.23 | -2.91 |
EPS (Diluted) | 0.13 | 0.15 | -1.27 | 0.43 | -1.23 | -2.91 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 19.58 | -12.62 | -23.44 | -33 | -7.73 | -64.35 |
Free Cash Flow Per Share | 0.33 | -0.21 | -0.43 | -0.62 | -0.21 | -2.08 |
Gross Margin | 56.31% | 42.42% | -101.67% | 50.43% | 11.06% | -253.45% |
Operating Margin | 14.07% | 10.72% | -151.08% | 25.81% | -57.13% | -481.87% |
Profit Margin | 15.71% | 12.83% | -142.91% | 21.98% | -86.74% | -491.65% |
Free Cash Flow Margin | 41.66% | -18.90% | -48.86% | -31.79% | -14.45% | -352.47% |
EBITDA | - | 7.16 | -72.48 | 27.15 | -29.7 | -87.33 |
EBITDA Margin | - | 10.72% | -151.08% | 26.16% | -55.50% | - |
D&A For EBITDA | - | 0 | 0 | 0.37 | 0.87 | 0.65 |
EBIT | 6.61 | 7.16 | -72.48 | 26.79 | -30.57 | -87.97 |
EBIT Margin | 14.07% | 10.72% | -151.08% | 25.81% | -57.13% | - |
Effective Tax Rate | 3.41% | 2.96% | - | 10.23% | - | - |
Revenue as Reported | 47 | 66.8 | 47.98 | 103.78 | 53.51 | 18.26 |